|
|
|
|
|
|
|
|
|
17.07.26 - 12:42
|
Why ′Big Pharma′ Will Never Make A Cheap Anti-Aging Drug (ZeroHedge)
|
|
|
Why 'Big Pharma' Will Never Make A Cheap Anti-Aging Drug
Authored by Ross Pomeroy via RealClearScience,
For years, scientists have hypothesized that safe, cheap, generic drugs like metformin and rapamycin could slow aging, based on promising findings in animal models. But despite the evidenced hope, little has been done to see if these drugs actually slow aging in humans. There have been no rigorous clinical trials exploring whether metformin or rapamycin prolong life and and boost health.
How is it possible that metformin and rapamycin, long used to respectively treat diabetes and prevent organ transplant rejection, have had their anti-aging potential ignored for so long? To conspiracy-minded critics of 'Big Pharma', the answer is obvious: there's no money in it. In this case, they seem to be correct. Speaking at the 12th Aging Research and Drug Discovery (ARDD) meeting convened at the University of Copenhagen last summer, industry leaders conceded the point.
"Repurposing cheap, off-pate...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.07.26 - 14:57
|
The Big Pharma Psychedelic Buyout Spree Has Begun (ZeroHedge)
|
|
|
The Big Pharma Psychedelic Buyout Spree Has Begun
Submitted by QTR's Fringe Finance
Massive validation for psychedelics…not as drugs, but as investments could be moments away. Just months after I argued for the millionth time that psychedelic drug developers were likely to become acquisition targets as the sector gained legitimacy, it looks like the first major domino may finally be falling.
According to a Bloomberg report published moments ago, Eli Lilly is in talks to acquire AtaiBeckley, one of the leading developers of next-generation psychedelic therapies. While nothing is finalized, Bloomberg reports a deal could be announced as soon as this week, with Lilly negotiating at a premium to AtaiBeckley's roughly $2 billion market value.
If this transaction gets across the finish line, I don't think it'll be remembered as an isolated acquisition. I think it'll be remembered as the moment Big Pharma officially entered the psychedelic arms race.
I've been writing for well over a year ...
|
|
|
|
|
|
|
|
|
|
|
|
|
16.07.26 - 05:06
|
Mainland China funds increase stakes in Hong Kong biotech amid surge of licensing deals (SCMP)
|
|
|
A growing number of mainland Chinese institutional fund managers have built up stakes in Hong Kong-listed biotechnology stocks over the past month, drawn by attractive valuations amid a surge in cross-border licensing deals in the sector.
China's largest mutual fund manager, E Fund Management, has taken a 7 per cent stake in gene-editing biotechnology firm Biocytogen Pharmaceuticals, buying additional 91,500 shares in the Beijing-based firm at an average price of HK$46.90 each on July 2,......
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
